THE PHENO SMART STUDY in the RHU SMART HAS STARTED !
The PhenoSMART study: characterization of new phenotypes of spinal muscular atrophy type 1, 2 or 3 after treatment with SMN restoring therapy received the ethics committee approval in second of February 2024.
The French national health and drug safety agency ANSM gave its its authorization on 11th of December 2023.
This is a prospective, longitudinal, multicenter, international
read more: WP 2.1 – Natural History
